Servizio Comunitario di Informazione in materia di Ricerca e Sviluppo - CORDIS

FP7

IP4PLASMA Report Summary

Project reference: 604048
Funded under: FP7-NMP

Periodic Report Summary 2 - IP4PLASMA (Industrial innovations based on EU intellectual property assets in the field of atmospheric plasma technology)

Project Context and Objectives:
The IP4Plasma project aims to bridge the gap between IPR protected laboratory-scale innovations in the field of atmospheric pressure plasma assisted chemical vapour deposition (AP-PA-CVD) technology and its industrial implementation for advanced surface treatment and nano-scale coating of materials. This will be done by demonstrating the suitability of the technology for existing and new industrial applications in the medical products and diagnostics sector. A mobile pilot scale plasma treatment system will be designed and built for this purpose based on existing experience and IPR protected know-how, and subsequently validated in end user production facilities. In the project, the manufacturers of atmospheric pressure plasma equipment and the end users of the technology will work together with research organisations and experts in technology innovation to overcome the barriers to commercial application of a unique IPR portfolio. This will create new business opportunities with large market potential for the industrial partner involved (mainly SMEs), and thus strengthen their global competitiveness.

Project Results:
The plasma reactor design and construction were finished in the beginning of the second year of the project. The new plasma reactor was tested and redesigned to improve the reliability and ease of use, after which it was delivered to Tosama d.o.o. for industrial demonstration in their wound dresssing manufacturing line. The demonstrations show good results for medical packaging applications and treatment of advanced wound dressings.
Demonstration of the medical diagnostic tests has also beed performed. The results show that tuberculosis diagnostic test can be performed now in 20minutes and that the manufacturing is feasible.

In addition, a surface potential measurement method for on-line monitoring of the efficiency and uniformity of plasma treatments has been developed and tested. Evaluation of the existing related IPR has been done, the market and valorisation studies for the wound dressings and diagnostics have been completed and the market analysis for the equipment sales has been started. Life cycle assessment of the applications are progressing with comparison to baseline methods. Two online training modules on plasma technologies has designed and are available at http://moodle.ip4plasma.eu/.

Potential Impact:
When atmospheric pressure plasma processing will be adopted for wider use it will create new business opportunities for the manufacturers of atmospheric pressure plasma systems, of which the European ones are currently in the leading position. Secondly, the technology will help end users to improve their products’ performance and cost efficiency, and to create new innovations, enabled By atmospheric pressure plasma deposition. The demonstrators of the project will be on medical diagnostics tests for tuberculosis and HIV, and on advanced wound dressings and medical packaging. Cheaper and faster diagnostics for TB and HIV will enable to screen a much larger population with the same amount of resources. This will enable broader and very likely also earlier detection of patients which can subsequently receive medical treated. This might drastically improve the life quality and life expectancy of the patients as well as prevent further spreading by active prevention measure. For advanced wound dressings and medical packaging costs savings and new functionalities are expected due to the use of plasma technologies.

List of Websites:
http://ip4plasma.eu

Contact

Kuusisto, Matti (Senior Consultant)
Tel.: +358 505539257
Fax: +358 925177888
E-mail
Record Number: 183919 / Last updated on: 2016-06-10
Information source: SESAM